Telix Pharmaceuticals (TLX) Payables (2023 - 2026)

Telix Pharmaceuticals (TLX) has reported Payables for 3 consecutive years, with $163.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Payables rose 185.05% year-over-year to $163.5 million; the TTM figure through Dec 2025 stood at $163.5 million (up 185.05% YoY), while the FY2025 annual figure was $163.5 million, up 185.05% from the prior year.
• Payables climbed to $163.5 million in Q4 2025 per TLX's latest filing, from $57.3 million in the prior quarter.
• Across five years, Payables topped out at $163.5 million in Q4 2025 and bottomed at $53.8 million in Q4 2023.
• Historically, Payables has averaged $91.5 million across 3 years, with a median of $57.3 million in 2024.
• Annual changes were most pronounced in 2024 — Payables climbed 6.56% — and 2025, when it jumped 185.05%.
• Telix Pharmaceuticals' Payables stood at $53.8 million in 2023, then gained by 6.56% to $57.3 million in 2024, then surged by 185.05% to $163.5 million in 2025.
• Business Quant data shows TLX's Payables at $163.5 million in Q4 2025, $57.3 million in Q4 2024, and $53.8 million in Q4 2023.